Oncology Brand Commercialization (PH68)

Resource Allocation
&nsbp;
 
 

  • Allocate Resources for Oncology Brands Through Development and Launch

    Use this report's 28 commercial variables to build your own, customized data sets for cancer drug launches. By combining spending and staffing data from the report's 28 different brand types, you can build resource benchmarks to fit your own unique challenges.

     

    The report's data sets are divided into 10 chapters:

    • Chapter 1: Drug Class — Explores resources for cytotoxics and innovative therapies
    • Chapter 2: Market Entrance — Explores resources for first-to-market brands and follow-on/me-too brands
    • Chapter 3: Indications — Explores resources for brands indicated to treat leukemia, breast cancer, lung cancer, prostate cancer and colorectal cancer
    • Chapter 4: Peak Sales — Explores resources for brands with projected peak annual sales of more than $1 billion, $500 million to $999 million and less than $500 million
    • Chapter 5:Line of Treatment — Explores resources for first-line, second-line and third-line therapeutics
    • Chapter 6: Clinical Profile — Explores resources for brands with favorable, average and unfavorable clinical profiles
    • Chapter 7: Industry Sector — Explores resources for brands commercially supported by major pharmaceutical companies and by biotechnology companies
    • Chapter 8: Competitive Landscape — Explores resources for brands with strong, average and weak competitive positions
    • Chapter 9: Promotional Infrastructure — Explores resources for brands with access to strong, average and weak internal resources
    • Chapter 10: Drug Delivery — Explores resources for brands delivered orally and intravenously
    Back to Top
  • Companies Included in Oncology Marketing Research (Partial List)

    • Amgen
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck KGaA
    • Novartis
    • Pfizer
    • Roche
    • Sanofi-Aventis
    • Wyeth
    Back to Top
  • Oncology Marketing Metrics

    Oncology Brand Commercialization: Resource Allocation divides averaged brand data into 28 divisions. By picking the data divisions that are most relevant to you, you can build customized oncology data sets to address any number of real or hypothetical marketing situations.

    Spending and Time Categories

    Time Periods:

    • Pre-Clinical
    • Phase I
    • Phase II
    • Phase III
    • Launch
    • 12-18 months post-launch

     

    Spending Categories:

    • Brand total
    • Brand activities
    • Market research
    • Thought leader development
    • Advertising

     

    Oncology Brand Breakdown

    Chapter 1: Drug Class

    • Cytotoxics
    • Innovative therapies

     

    Chapter 2: Market Entrance

    • First-to-market brands
    • Follow-on/me-too brands

     

    Chapter 3: Indications

    • Leukemia
    • Breast cancer
    • Lung cancer
    • Prostate cancer
    • Colorectal cancer

     

    Chapter 4: Peak Sales

    • Brands with projected peak annual sales of more than $1 billion
    • Brands with projected peak annual sales of $500 million to $999 million
    • Brands with projected peak annual sales of less than $500 million

     

    Chapter 5: Line of Treatment

    • First-line therapeutics
    • Second-line therapeutics
    • Third-line therapeutics

     

    Chapter 6: Clinical Profile

    • Brands with favorable clinical profiles
    • Brands with average clinical profiles
    • Brands with unfavorable clinical profiles

     

    Chapter 7: Industry Sector

    • Brands commercially supported by major pharmaceuticals companies
    • Brands commercially supported by biotechnology companies

     

    Chapter 8: Competitive Landscape

    • Brands with strong competitive positions
    • Brands with average competitive positions
    • Brands with weak competitive positions

     

    Chapter 9: Promotional Infrastructure

    • Brands with access to strong internal resources
    • Brands with access to average internal resources
    • Brands with access to weak internal resources

     

    Chapter 10: Drug Delivery

    • Brands delivered orally
    • Brands delivered intravenously
    Back to Top
  • Back to Top